On Sept. 16 Novo Nordisk (NYSE: NVO) and Korro Bio (NASDAQ: KRRO) announced that they'd be starting a new drug-development collaboration worth hundreds of millions of dollars, in an area that most ...

Novo Nordisk and NanoVation will collaborate on two lead programs to develop base-editing therapies for certain rare genetic diseases. NanoVation’s lcLNP technology has demonstrated the ability ...

Shares of Novo Nordisk NVO gained 4.2% on Sept. 11 after the company presented encouraging detailed efficacy data from the early-stage study of its new, investigational oral obesity pill ...

On Wednesday, Cantor Fitzgerald reaffirmed its positive stance on Novo Nordisk (NYSE:NVO), maintaining an Overweight rating and a price target of $160.00. The reaffirmation came as Novo Nordisk ...

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Novo Nordisk NVO in the last three months. The table below offers a condensed view of their ...

COPENHAGEN, Sept 11 (Reuters) - Novo Nordisk's highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side ...

At the European Association for the Study of Diabetes annual meeting, Novo Nordisk A/S (NYSE:NVO) shared an abstract with data from the company’s next-generation weight loss candidate ...

Novo Nordisk A/S (NVO) has turned into one of the most valuable pharma companies in the world thanks to its success with weight loss drug Wegovy. But growth has recently slowed down, and the ...

(RTTNews) - Novo Nordisk said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Wegovy ...

With the transactions stated above, Novo Nordisk owns a total of 13,563,880 B shares of DKK 0.10 as treasury shares, corresponding to 0.3% of the share capital. The total amount of A and B shares ...